NEUROPROTECTION AND NEUROREGENERATION: PERSPECTIVES IN THE TREATMENT OF GLAUCOMA

Kanski’s Clinical Ophthalmology, 9th…

This monograph is intended for students and specialists in ophthalmology, neurology, as well as for doctors of various medical specialties. Glaucoma is the second most common cause of irreversible blindness in the world.

This disease is considered to be a multifactorial, neurodegenerative process characterized by progressive opticopathy, pathological changes in the visual field and loss of ganglion cells. The number of patients in the world by 2021 will grow to 79.6 million people or 2% of the population after the age of 40.

The Eye, 5th Edition

In addition to medical, laser and surgical treatment, in recent years, neuroprotection, the main task of which is to prevent the irreversible death of ganglion cells, has been increasingly introduced. Lowering intraocular pressure remains a major strategy that improves the prognosis of the disease.

In this regard, neuroprotection remains one of the most promising directions for improving the prognosis and delaying the progression of this disease, which leads to irreversible blindness.